Related Experiment Video

Updated: Jul 16, 2026

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

Recombinant human deoxyribonuclease in infants with respiratory syncytial virus bronchiolitis

Ruben Boogaard1, Anthon R Hulsmann2, Leoniek van Veen3

  • 1Department of Pediatric Pulmonology, Erasmus MC-Sophia Children's Hospital, Rotterdam, Netherland.

Chest
|March 16, 2007
PubMed

Insights

Recombinant human deoxyribonuclease (rhDNase) did not shorten hospital stays or reduce oxygen needs for infants with respiratory syncytial virus (RSV) bronchiolitis. This study found no significant benefits in treating RSV bronchiolitis with rhDNase.

Area of Science:

  • Pediatric Pulmonology
  • Viral Respiratory Infections
  • Pharmacological Interventions

Background:

  • Respiratory syncytial virus (RSV) bronchiolitis in infants often requires hospitalization and supportive care.
  • Current treatments like bronchodilators and steroids do not effectively shorten hospital stays.
  • Viscous mucus and free DNA in RSV infections contribute to hypoxia and airway obstruction.

Purpose of the Study:

  • To evaluate the efficacy of nebulized recombinant human deoxyribonuclease (rhDNase) as a mucolytic agent.
  • To determine if rhDNase can reduce the length of hospital stay in infants with RSV bronchiolitis.
  • To assess secondary outcomes including oxygen duration and symptom improvement.

Main Methods:

  • A multicenter, randomized, double-blind, controlled trial was conducted.
  • 225 oxygen-dependent infants hospitalized with RSV bronchiolitis were enrolled.
  • Participants received either nebulized rhDNase (2.5 mg twice daily) or placebo until hospital discharge.

Main Results:

  • No statistically significant difference was observed in the length of hospital stay between the rhDNase and placebo groups (p = 0.19).
  • The duration of supplemental oxygen also showed no significant difference between the groups (p = 0.07).
  • There were no significant improvements in symptom scores or reductions in intensive care admissions.

Conclusions:

  • Nebulized rhDNase administration did not reduce hospital stay duration for infants with RSV bronchiolitis.
  • rhDNase did not decrease the need for supplemental oxygen in this patient population.
  • The study concluded that rhDNase is not effective for managing hospitalized infants with RSV bronchiolitis.
Abstract

More Related Videos

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay09:14

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay

Published on: January 26, 2019

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

Related Concept Videos

Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Acute Respiratory Failure-IV01:23

Acute Respiratory Failure-IV

Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without causing...